Sagawa T, Takayama T, Oku T, Hayashi T, Ota H, Okamoto T, Muramatsu H, Katsuki S, Sato Y, Kato J, Niitsu Y
Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
Gut. 2003 Mar;52(3):334-9. doi: 10.1136/gut.52.3.334.
In recent years, there has been an increasing number of cases of early gastric cancer (T1, NX) with intramucosal invasion, which are untreatable by surgical or endoscopic mucosal resection (EMR) because of their high risk. Currently, no adequate treatment is available for such patients.
The main objective of this study was to evaluate whether argon plasma coagulation (APC) is an effective and safe modality for treating early gastric cancer untreatable by surgical resection or EMR.
The study group comprised 20 men and seven women diagnosed with gastric cancer with intramucosal invasion who were considered poor candidates for surgical resection or EMR due to risk factors such as severe cardiac failure or thrombocytopenia. Irradiation conditions for APC treatment were determined using swine gastric mucosa. We used an argon gas flow of 2 l/min at a power setting of 60 W and a maximum irradiation time of 15 s/cm(2). The follow up period of the 27 patients ranged from 18 to 49 months (median 30 months).
All lesions were irradiated easily, including areas anatomically difficult for EMR such as the gastric cardia or the posterior wall of the upper gastric body. In 26 of 27 patients (96%) there was no evidence of recurrence during the follow up period (median 30 months). One patient showed recurrence six months after the treatment but was successfully retreated. No serious complications were found in any of the 27 patients but three patients (11%) experienced a feeling of abdominal fullness.
APC is a safe and effective modality for treatment of early gastric cancer with intramucosal invasion untreatable by surgical resection or EMR. However, further observations are necessary to determine the long term prognosis of patients undergoing this treatment.
近年来,早期胃癌(T1,NX)伴黏膜内浸润的病例数量不断增加,由于其风险高,无法通过手术或内镜黏膜切除术(EMR)进行治疗。目前,此类患者尚无足够的治疗方法。
本研究的主要目的是评估氩等离子体凝固术(APC)对于无法通过手术切除或EMR治疗的早期胃癌是否是一种有效且安全的治疗方式。
研究组包括20名男性和7名女性,他们被诊断为患有黏膜内浸润的胃癌,由于严重心力衰竭或血小板减少等风险因素,被认为不适合进行手术切除或EMR。使用猪胃黏膜确定APC治疗的照射条件。我们在功率设置为60W、氩气流量为2l/min且最大照射时间为15s/cm²的条件下进行治疗。27例患者的随访期为18至49个月(中位值30个月)。
所有病变均易于照射,包括EMR在解剖学上难以处理的区域,如胃贲门或胃体上部后壁。27例患者中有26例(96%)在随访期(中位值30个月)内无复发迹象。1例患者在治疗后6个月出现复发,但再次治疗成功。27例患者中均未发现严重并发症,但有3例患者(11%)出现腹胀感。
APC是治疗无法通过手术切除或EMR治疗的伴有黏膜内浸润的早期胃癌的一种安全有效的方式。然而,需要进一步观察以确定接受该治疗患者的长期预后。